Pharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of [amount hidden] every 28 days

What Was Tested

Researchers studied Somatostatin and Lanreotide in this randomized controlled trial publication.

Who Took Part

According to the abstract, 18 patients were involved.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

A total of 18 patients with acromegaly were recruited; six patients were randomized to each treatment.

How the Study Was Run

The design is described as randomized and double-blind.

Because people in this Somatostatin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the patients and researchers unaware of who received Somatostatin.

Serum GH and IGF-1 levels were assessed before each administration and at the end of the study.

What Was Measured

The subject headings attached to it are Acromegaly, Analysis of Variance, Antineoplastic Agents, Gels, Growth Hormone, Insulin-Like Growth Factor I and Linear Models.

What This Means in Plain Language

The paper is a randomized and double-blind study of Somatostatin and Lanreotide in 18 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2005 (Clinical endocrinology), a journal based in England.

More context: the Somatostatin compound page and the Lanreotide compound page, all human trials.